On February 10, 2022, the Centers for Medicare & Medicaid Services (CMS) issued a National Coverage Decision to expand reimbursement for lung cancer screening with low-density computed tomography (LDCT).
Personalized medicine, in which the molecular profile of each patient’s tumor helps customize the course of treatment, has been useful in treating many types of cancer, including non-small cell lung cancer (NSCLC). However, for patients diagnosed with extensive small cell lung cancer (SCLC), the treatment plans are mostly one size fits all.
MET is a gene that encodes for a MET protein. It is an important signaling protein known to play many different important roles, from the development of embryos to wound healing in adults. However, when specific MET gene alterations occur, they can also lead to the development of non-small cell lung cancer (NSCLC).
Support and understanding from someone who has already walked the lung cancer path can be essential to navigating a lung cancer diagnosis. Whether you are new to your diagnosis or have been navigating the disease for many years, you can find encouragement, share information, and give support by connecting with others affected by lung cancer.
The development of “targeted therapies” which block the function of mutant proteins within tumor cells has revolutionized the treatment landscape for many cancers, most of all lung cancer. EGFR is one such protein which is often altered (mutated) in lung cancers. Over the past decade, multiple EGFR targeted therapies have been developed, with each generation of drugs becoming increasingly potent.
